Background: Hepatitis C virus (HCV) infection is associated with chronic inflammation; yet studies show greater interleukin (IL)-6, but lower C-reactive protein (CRP) levels. We determined whether liver fibrosis severity and HCV replication affect the ability of IL-6 to stimulate the production of CRP from the liver.
Background
Coinfection with hepatitis C virus (HCV) is associated with increased vascular disease in HIV-infected adults [1, 2] ; inflammation is postulated as a key underlying mechanism [3] [4] [5] . C-reactive protein (CRP) is a widely used clinical marker of inflammation. The inflammatory marker interleukin (IL)-6 is a potent stimulator of CRP production in the liver and has also been associated with vascular disease and death [6] [7] [8] , but is generally not tested on a clinical basis. Because the liver is the primary source of CRP, its value as a marker of vascular risk and death has been questioned in the setting of HCV and HIV/HCV coinfection.
Studies show that HIV/HCV coinfection is associated with higher IL-6, but lower CRP levels compared to those with neither HIV nor HCV infection [9, 10] . Liver fibrosis severity and HCV replication are postulated mechanisms for the attenuated CRP level. The paucity of data describing the effect of liver fibrosis severity on IL-6 and CRP levels likely reflects the difficulties of pursuing liver biopsy in large numbers of patients. In addition, few studies have examined the association of HCV replication with IL-6 and CRP levels. While HCV replication is thought to exploit pathways involved in low-density lipoprotein (LDL) metabolism [11, 12] , the effects of altered lipid metabolism on IL-6 and CRP levels is unclear. An understanding of the relationship between HCV infection, liver fibrosis severity, and inflammation is of clinical importance (because liver fibrosis may remain even after successful HCV treatment) and could shed light on potential mechanisms by which chronic HCV infection leads to extrahepatic injury.
We characterize levels of IL-6 and CRP in the setting of HIV and HCV infection, and determine whether liver fibrosis severity affects levels of inflammation. We used ultrasound-based transient elastography to assess liver fibrosis severity in a cohort of women with HCV infection (in the presence or absence of HIV), HIV monoinfection, and neither HIV nor HCV infection. In HCV-infected women, we also investigated whether HCV viremia and/ or alterations in lipid parameters affect IL-6 and CRP levels. We hypothesized that liver fibrosis severity and HCV replication would blunt CRP levels despite increased IL-6 levels resulting from chronic HIV/HCV infection.
Methods

Study population
The Women's Interagency HIV Study (WIHS) is a prospective cohort that investigates the progression of HIV in women with and at risk for HIV. A total of 4137 women (3067 HIV-infected, 1070 HIV-uninfected) were enrolled from six consortia across the United States (Bronx, New York; Brooklyn, New York; Chicago, Illinois; Los Angeles, California; San Francisco, California; and Washington, District of Columbia) in either 1994-1995 (n ¼ 2623), 2001-2002 (n ¼ 1143), or 2011-2012 (n ¼ 371). Baseline socio-demographic characteristics and HIV risk factors were similar between HIV-infected and uninfected women [13, 14] . An institutional review board approved study protocols and consent forms, and each study participant gave written informed consent. Every 6 months, participants complete a comprehensive physical examination and an interviewer-administered questionnaire, which collects information on demographics, disease characteristics, and specific antiretroviral therapy (ART) use, and provide biological specimens.
From November 2010 through October 2012, 381 women from the San Francisco, Chicago, and Washington, District of Columbia sites agreed to participate in a transient elastography substudy and underwent transient elastography using the Fibroscan (Echosens, Paris, France). The transient elastography substudy and Fibroscan procedure have been previously described [15] . Women who were excluded were older (52 vs. 48 years), had greater BMI (28 vs. 26 kg/m 2 ), greater waist circumference (93 vs. 80 cm), and reported drinking more alcohol (59 vs. 52%). However, the excluded and included participants had similar prevalences of HIV (45 vs. 51%) and HCV (28 vs. 23%). A total of 306 women (164 HIVþ/HCVÀ, 10 HIVÀ/HCVþ, 73 HIVþ/ HCVþ, 59 HIVÀ/HCVÀ) were included in the analysis. Sixteen women who were HCV-seropositive, but HCV-RNA-undetectable, were included in the HIVþ/ HCV group.
Measurement of interleukin-6 and C-reactive protein
Interleukin-6 and CRP were measured from frozen sera that were stored at À708C. IL-6 was measured by highsensitivity enzyme-linked immunosorbent assay (ELISA) (Quantikine HS Human IL-6 Immunoassay, R&D Systems, Minneapolis, Minnesota, USA) (lower limit of detection 0.11 pg/ml. The intra-assay coefficient of variation was 7.4% and the interassay coefficient of variation ranged from 6.5 to 9.6%. CRP was measured using the BNII nephelometer from Dade Behring (Deerfield, Illinois, USA), which utilizes a particleenhanced immunonephelometric assay (lower limit of detection 0.17 mg/l). The interassay coefficient of variation for CRP ranged from 1.1 to 4%.
Covariates
Key covariates included HIV and HCV infection status (defined by documentation of a positive HIV enzyme immunoanalysis (EIA) confirmed by western blot and a positive HCV EIA confirmed by detectable HCV-RNA, respectively). Other candidate covariates included liver fibrosis severity estimated using transient elastographymeasured liver stiffness; demographic factors (age, race/ ethnicity), menopausal status, lifestyle factors [history of injection drug use; alcohol use (none, light drinking 1-15 g/day, moderate drinking 15-30 g/day, heavy drinking >30 g/day); marijuana use (none, occasional, daily); smoking (none, current, past)], body composition and metabolic factors [waist circumference, BMI (calculated from height and weight in kg/m 2 ), diabetes mellitus (defined by a confirmed elevated fasting glucose, elevated hemoglobin A1C >6.5%, or self-report of antidiabetes medications), insulin resistance estimated using the homeostasis model assessment, and use of antidiabetes medications]. In analyses among HIVinfected women, current CD4 þ cell count, nadir CD4 þ cell count, current HIV-RNA level, history of clinical AIDS, and current use of HAART and ART by class were assessed. In analyses among HCV-infected women, HCV-RNA level and HCV genotype were also assessed. We also additionally adjusted for fasting lipids [high-density lipoprotein (HDL), LDL, triglycerides, and total cholesterol), apoplipoprotein B (ApoB), and use of lipid-lowering therapy. In exploratory analyses, we controlled for liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST)]. Multiple imputation using the Markov chain Monte Carlo method was used to impute missing covariates [16] .
Statistical analysis
We compared demographic and clinical characteristics among four groups: HIV-monoinfected, HCV-monoinfected, HIV/HCV-coinfected, and those with neither infection, using the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables.
We used Spearman's coefficients to determine correlations between continuous parameters in four groups: HIV-monoinfected, HCV-infected with significant fibrosis, HCV-infected without significant fibrosis, and those with neither infection. A liver stiffness value greater than 7.1 kPa was used to define significant fibrosis (which corresponds to fibrosis stage 2 or greater in validated studies of HCV-infected patients) [17] . We also tested an alternative cut-off of liver stiffness greater than 9.3 kPa, which has been validated in a study of US injection drug users to distinguish histologic stage 0-1 fibrosis from stage 2 or higher fibrosis [18] .
Interleukin-6 and CRP were found to be right-skewed and showed evidence of heteroscedasticity, even after log transformation. Use of log-linear ordinary least squares in such circumstances has been shown to lead to biased estimates. We therefore used generalized linear regression with a log link function and pseudo-maximum likelihood estimator, using a robust variance estimator to adjust for potential overdispersion in the models [19] [20] [21] . The relative percentage difference was then estimated to evaluate the association of HIV and HCV infection (stratified by significant fibrosis) with IL-6 and CRP levels.
To determine whether HIV monoinfection and HCV infection were independently associated with IL-6 and CRP, multivariable models were sequentially adjusted for demographic and lifestyle factors, metabolic parameters, and liver fibrosis severity. Age and race/ethnicity were retained in all models. We then constructed separate models in participants with HCV infection (with and HIV, hepatitis C virus, liver fibrosis and inflammation Shah et al. 1327 without HIV) and HIV infection alone in order to examine the associations of demographic, lifestyle, metabolic risk factors, and liver stiffness severity within each group. HIV-related factors were included in models of HIV-infected women, and HCV-related factors were included in models of HCV-infected women. A stepwise regression, with a P value of less than 0.10 or less was used for entry and retention; the candidate variables were selected on the basis of their hypothesized associations with inflammation.
All analyses were conducted using the SAS system, version 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Population characteristics
The characteristics of the 306 women included in this analysis, stratified by HIV and HCV status, are shown in Table 1 . Approximately two-thirds of all women were African American with the largest proportion among the HCV-infected group. HCV-infected women were more likely than HCV-uninfected women to be older, menopausal, and to report using tobacco, marijuana, or alcohol. BMI and waist circumference were not statistically different among the four groups, but HCVinfected women had lower ApoB and LDL than HCVuninfected women. On the contrary, HIV-infected women appeared to have lower HDL and higher triglyceride levels than HIV-uninfected women. HCVinfected women had higher median liver stiffness values compared to HCV-uninfected women. Among the HIVinfected women, coinfection with HCV was associated with lower current and nadir CD4 þ cell counts, slightly higher HIV-RNA levels, a history of AIDS, and a lower prevalence of HAART use. HIV/HCV-coinfected women had higher HCV-RNA levels compared to HCV-monoinfected women. The HCV-monoinfected and HIV/HCV-coinfected women were combined in subsequent analysis, because there were only 10 HCVmonoinfected women and these women had similar demographic, metabolic, and liver stiffness characteristics to the HIV/HCV-coinfected women.
Association of HIV monoinfection and hepatitis C virus infection with interleukin-6 and C-reactive protein levels Interleukin-6 levels were highest in the HCV-infected women, whereas HIV-monoinfected women and uninfected controls had similar levels (median 1.5 vs. 0.9 vs. 0.9 pg/ml, respectively; P < 0.0001; Fig. 1 ). By contrast, CRP levels were lowest in the HCV-infected women, intermediate in the HIV-monoinfected women, and highest in the uninfected controls (median 0.7 vs. 1.2 vs. 1.4 mg/dl, respectively; P ¼ 0.03). We then performed multivariable analysis, which showed that HCV infection was associated with a 119% higher IL-6 level relative to controls [95% confidence interval (CI) 42%, 237%] after adjustment for demographic, behavioral, and clinical risk factors. By contrast, HCV infection was associated with 43% lower CRP levels (95% CI À62%, À14%) compared to controls after multivariable adjustment. HIV monoinfection was associated with a 15% higher IL-6 level (95% CI À22%, 70%), but 17% lower CRP level (95% CI À40%, 15%) relative to controls. In multivariable models that included both IL-6 and CRP, after controlling for levels of IL-6, HCV remained associated with 54% lower CRP in those with fibrosis (95% CI À71%, À25%) and 47% lower CRP in those without fibrosis (95% CI À66%, À16%), whereas HIV-monoinfected women had a 20% lower CRP (95% CI À41%, 9%) compared to controls.
Association of hepatitis C virus infection and liver fibrosis with interleukin-6 and C-reactive protein
In order to understand the contributions of HCV and liver fibrosis to IL-6 and CRP levels, we next stratified 1328 AIDS 2015, Vol 29 No 11 HCV-infected women according to the presence or absence of significant fibrosis (i.e. liver stiffness >7.1 kPa). Figure 2 shows the association of HCV infection, either with or without significant fibrosis, and HIV monoinfection with IL-6 and CRP levels relative to controls. HIV-monoinfected women and controls were not stratified by the presence or absence of significant fibrosis, because few met criteria for significant fibrosis [n ¼ 18 (11%) for HIVand n ¼ 6 (10%) for controls]. After multivariable adjustment, HCV-infected women with fibrosis had a 2.7-fold higher IL-6 level compared to controls (95% CI 146%, 447%), whereas HCV-infected women without fibrosis and HIV-infected women had a 12% (95% CI À31%, 80%) and 7% (95% CI À26%, 57%) higher IL-6 level, respectively, compared to controls, neither of which was statistically significant. By contrast, levels of CRP were 28% lower in HCV-infected women with fibrosis (95% CI À55%, 15%) and 47% lower in HCV-infected women without fibrosis (95% CI À68%, À12%) compared to controls, whereas HIV-monoinfected women had 12% lower CRP (95% CI À37%, 21%) compared to controls. Results were similar when we defined significant fibrosis by liver stiffness greater than 9.3 kPa (data not shown).
Relationship of interleukin-6 and C-reactive protein levels according to HIV and hepatitis C virus infection status
Interleukin-6 was positively correlated with CRP, irrespective of HIV and HCV infection status, with Spearman's correlation (r) ranging from 0.4 to 0.6 ( Fig. 3) . However, the intercept was shifted downward in the HCV-infected women; so for any given IL-6 level, the CRP level was significantly lower than in the HIVmonoinfected and the control women (P < 0.001). Among the HCV-infected women with fibrosis, CRP levels appeared to be lower at all levels of IL-6 compared to HCV-infected women without fibrosis, but the difference was not statistically significant (P ¼ 0.63). When the 18 HIV-monoinfected women with significant fibrosis and the six control women with significant fibrosis were excluded, the Spearman's correlations and P values did not change.
Factors associated with interleukin-6 and C-reactive protein levels among hepatitis C virus-infected women Table 2 shows factors associated with IL-6 and CRP in the HCV-infected women. In unadjusted analysis, higher HCV-RNA level was associated with 20% lower IL-6 level (per HCV-RNA doubling), and liver stiffness was associated with 31% higher IL-6 level per doubling, although the latter association did not reach significance. After multivariable adjustment, the association of HCV-RNA weakened (16% lower) and was no longer statistically significant, whereas the association of greater liver stiffness with higher IL-6 levels strengthened (34% higher) and was significant. When examining the factors associated with CRP, in unadjusted analysis, greater waist circumference (per 10 cm increase) was associated with 4% higher CRP, and greater liver stiffness was associated with 33% higher CRP levels, whereas per doubling of HCV-RNA was associated with 7% lower CRP levels that did not reach significance. After multivariable adjustment, waist circumference remained strongly associated with 4% higher CRP levels, whereas liver stiffness weakened (21% lower) and was no longer significantly associated. By contrast, each doubling of HCV-RNA level was significantly associated with 9% lower CRP levels. Additional adjustment for lipid factors did not show an association of LDL with IL-6 (À28% per doubling; 95% CI À48%, 29%) or CRP levels (À16% per doubling; 95% CI À49%, 37%); greater HDL was associated with lower IL-6 (À13% per doubling; 95% CI À62%, 98%) and lower CRP (À44%; 95% CI À67%, À5%). 
Factors associated with interleukin-6 and C-reactive protein levels among HIV-infected women
Among the HIV-monoinfected women, there was little association of any demographic, behavioral, metabolic, liver, or HIV-related factors with IL-6 levels in unadjusted and adjusted analysis ( Table 3) . By contrast, in unadjusted analysis, current smoking was associated with 91% higher CRP levels and marijuana use was associated with 113% higher CRP levels. Among the HIV-related factors, having an undetectable HIV-RNA level was associated with 32% lower CRP levels and per doubling of CD4 þ cell count was associated with 39% higher CRP levels. After multivariable adjustment, having an undetectable HIV-RNA level was nonsignificantly associated with 17% lower CRP levels and per doubling of CD4 þ cell count was associated with 29% higher CRP levels. There was little association of liver stiffness with CRP levels (À3% per doubling; 95% CI À32%, 37%).
Discussion
In our study of women with HIV, HCV, and neither infection, we report several important findings that elucidate the relationship of HIV, HCV, and liver fibrosis severity with levels of IL-6 and CRP. We found that the expected positive correlation between IL-6 and CRP was preserved regardless of the infection status. However, CRP levels were significantly lower for any given IL-6 level in HCV-infected women, suggesting attenuation of the stimulatory effect of IL-6 on CRP in the presence of HCV infection. We also found that HCV-infected women with significant liver fibrosis had 2.7-fold greater IL-6 levels compared to uninfected controls, but in the absence of significant fibrosis, IL-6 levels did not appear to be substantially elevated. By contrast, HCV-infected women had a lower CRP when compared to uninfected controls. Furthermore, among HCV-infected women, higher HCV-RNA level was associated with lower CRP levels. Taken together, our findings suggest that there is a strong association between HCV-related liver fibrosis and higher IL-6 levels, but HCV replication (and not liver fibrosis) likely blunts the stimulatory effect of IL-6 on CRP, resulting in relatively lower CRP levels. 
99% (À49%, 674%) 54% (À37%, 279%) 39% (À52%, 301%) 40% (À46%, 264%) P ¼ 0.32 P ¼ 0.34 P ¼ 0.54 P ¼ 0.50 Hispanic (vs. Caucasian) 36% (À76%, 669%) 71% (À48%, 466%) 11% (À72%, 351%) 18% (À67%, 329%)
Metabolic factors
Waist circumference (per 10 cm) 2% (À1%, 4%) 0% (À2%, 3%) 4% (2%, 6%) 4% (2%, 6%) P ¼ 0.14 P ¼ 0.74 P < 0.0001 P < 0.0001 HCV-related factors Liver stiffness (per doubling) 31% (À1%, 74%) 34% (8%, 66%) 33% (4%, 70%) 21% (À6%, 57%) P ¼ 0.06 P ¼ 0.009 P ¼ 0.02 P ¼ 0.141 HCV-RNA (per doubling) À20% (À27%, À12%) À16% (À30%, 1%) À7% (À26%, 3%) À9% (À18%, 0%) P < 0.0001 P ¼ 0.06 P ¼ 0.17 P ¼ 0.05 CI, confidence interval; CRP, C-reactive protein; HCV, hepatitis C virus; IL, interleukin. a Outcomes are log-transformed; results are back-transformed to produce estimated relative differences in inflammatory marker attributable to each factor. Estimates are from multivariable Poisson regression models.
Our finding that HIV/HCV-coinfected women had greater IL-6 and lower CRP levels is consistent with a study by Salter et al. [9] in HCV-infected (with and without HIV infection) and uninfected adults. The above study also examined the association of liver markers (albumin, AST, and ALT) with CRP, but not with IL-6.
Our study extends the findings of the above-mentioned study by examining the complex inter-relationship of IL-6, CRP, and liver fibrosis severity (using direct measurement of liver stiffness by transient elastography) in women with HIV monoinfection, HCV infection (with and without HIV infection), and those with neither infection.
First, we demonstrated preservation of the relationship of higher IL-6 with higher CRP in all groups. However, among the HCV-infected women, the IL-6-associated increase in CRP was blunted compared to those without HCV infection, suggesting an altered response to IL-6 stimulation that is specific to HCV infection. Second, we found that the association of HCV infection (in the absence or presence of HIV) with higher IL-6 levels is likely driven by the presence of liver fibrosis. Our findings are corroborated by studies [22, 23] of HIV-infected adults at risk for liver disease that showed that advanced fibrosis/ cirrhosis measured by indirect serum fibrosis markers was associated with higher IL-6 levels. However, we showed that in the absence of fibrosis, there was little difference in IL-6 levels between HCV-infected and control women, supporting a causal role of HCV-associated liver fibrosis with IL-6 levels.
By contrast, we found little role for liver fibrosis in the association of HCV with CRP. Salter et al. [9] also found little association of liver enzymes and markers of liver function with lower CRP, as did another small study of HIV/HCV-coinfected adults, but this latter study did not find a correlation of liver stiffness with either IL-6 or CRP [24] . Interestingly, in our study, HCV-infected women without fibrosis appeared to have 47% lower CRP levels compared to the 28% lower CRP levels in those with fibrosis, suggesting that in the absence of fibrosis, the blunting effect of HCV infection on CRP production are not opposed by the stimulatory effect of IL-6 (observed in the presence of fibrosis). Our finding provides evidence for the role of HCV infection itself and not liver fibrosis on CRP levels.
We also found that HCV viremia was associated with lower CRP levels. These findings are consistent with the study by Salter et al. [9] , although another study [25] did not find an expected increase in CRP level after reductions in HCV-RNA level with HCV treatment, suggesting that other HCV-related factors may contribute to the lower CRP levels. The phenomenon of 'immune tolerance' has been proposed as a mechanism by which HCV replication lowers CRP [26] , in which case the local host immune response becomes altered or refractory to continued HCV replication in hepatocytes. HCV replication may be associated with depressed IL-6 levels and in turn depressed stimulation of CRP production. While we found that HCV replication was associated with lower IL-6 levels in unadjusted analysis, we demonstrated that further adjustment for IL-6 in models of CRP in the HCV-infected women strengthened the association of HCV-RNA with lower CRP levels, suggesting that the relationship of HCV-RNA with HIV, hepatitis C virus, liver fibrosis and inflammation Shah et al. 1331 Table 3 . Factors associated with interleukin-6 and C-reactive protein in the 164 HIV-monoinfected women.
HIV-monoinfected women
IL-6 CRP
Unadjusted Adjusted a Unadjusted Adjusted a % difference (95% CI), P value % difference (95% CI), P value Demographic factors Age (per decade) 4% (À8%, 17%) 4% (À8%, 18%) 5% (À14%, 28%) 6% (À13%, 29%)
1% (À24%, 34%) À1% (À26%, 34%) À5% (À39%, 49%) À16% (À46%, 30%)
À11% (À41%, 35%) À23% (À43%, 32%) À40% (À72%, 26%) À36% (À68%, 27%)
Behavioral factors
Current smoking 12% (À11%, 41%) 14% (À11%, 46%) 91% (34%, 172%) 62% (11%, 135%)
À16% (À37%, 11%) À22% (À42%, 5%) 113% (48%, 207%) 86% (28%, 169%)
HIV-related factors
Undetectable HIV RNA 3% (À18%, 29%) À2% (À23%, 24%) À32% (À53%, 0%) À17% (À42%, 20%)
À4% (À9%, 1%) À5% (À11%, 1%) 39% (12%, 73%) 29% (5%, 58%) lower CRP levels is independent of IL-6. We also examined whether HCV-associated alterations in lipid metabolism might play a role, as studies have shown that HCV is associated with lower LDL levels [27, 28] . We did not find an association of serum lipid and lipoproteins with CRP levels. Further study is needed to determine how HCV viral replication might inhibit CRP production.
Similar to findings in the general population [29, 30] , we found that waist circumference, a marker of visceral obesity, was associated with higher CRP levels in HCVinfected women. Among the HIV-monoinfected women, current smoking and marijuana use were associated with higher CRP levels, as was a higher CD4 þ cell count. Smoking has been associated with higher CRP levels [10] ; whether or not there is a direct association of marijuana with higher CRP levels is unclear. Although unexpected, the association of higher CD4 þ could represent a restoration to health, and thus restoration of fat stores and higher CRP levels.
Finally, consideration of our findings within the broader purview of studies of CRP and IL-6 in HIV and HCV infection is important. In our cohort of women, median CRP levels were 46-74% and 24% lower than those reported in other cohort studies of HIV-infected women [10, 31] and HIV/HCV-coinfected women [10] , respectively. Our study was conducted in the era of potent ART, which is reflected in high median CD4 þ cell counts (>500 cells/ml), and could explain the lower IL-6 and CRP levels than reported in other studies. We also observed that the median CRP level in control women was slightly higher than in HIV-infected women, whereas IL-6 levels were comparable between the HIV-monoinfected and control women. Uninfected women in the WIHS are enrolled on the basis of having similar high-risk behaviors as HIV-infected women.
Our study has several limitations. First, the cross-sectional design did not allow us to examine causal relationships. Second, we had few HCV-monoinfected women, but their demographic and metabolic characteristics were similar to the HIV/HCV-coinfected women. This allowed us to pool the two groups and increase our sample size of HCV-infected women. Third, our results may not generalize to men. Fourth, women with greater adiposity were more likely to be excluded, a factor which has been associated with both inflammation and liver fibrosis. This exclusion may have reduced our ability to detect associations by limiting the spectrum of inflammation and fibrosis. However, we were able to find differential and independent associations of HCV with inflammation. Future studies using the Fibroscan XL probe are needed in order to study liver fibrosis severity in those with obesity. Fifth, it is plausible that serum IL-6 and CRP levels may not accurately reflect the hepatic milieu (although peripheral IL-6 and CRP levels may be more relevant in terms of risk stratification). Finally, we recognize that the relationship of HCV and markers of inflammation is complex, given that some biomarkers are synthesized in the liver or may be more affected by HIV replication. A composite measure of multiple elevated biomarkers has been examined in the setting of HIV and HCV infection and found to be associated with HIV and HCV viremia [22] . Future study of other markers of inflammation is needed in order to understand the complex relationship of HCV infection with inflammation and activation.
In conclusion, we found that liver fibrosis severity is associated with greater IL-6 levels, but the stimulatory effect of IL-6 on CRP is blunted by HCV replication (and not liver fibrosis severity). Our findings have several important clinical implications in light of new curative anti-HCV therapies. Such therapies have shown promise in eradicating HCV infection, but may not completely resolve liver fibrosis. Studies are needed in the new HCV treatment era to see if pre-existing liver fibrosis, IL-6, and the presumed rebound in CRP levels after HCV cure will be associated with increased vascular events, as well as other organ and tissue injury affected by chronic HCV infection.
